BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 2019;68:2206-13. [PMID: 31462554 DOI: 10.1136/gutjnl-2019-318981] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang DQ, Lim SG. Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes. Clin Liver Dis (Hoboken) 2020;16:262-5. [PMID: 33489099 DOI: 10.1002/cld.983] [Reference Citation Analysis]
2 Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol 2022;76:1249-62. [PMID: 35589248 DOI: 10.1016/j.jhep.2021.11.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lee HW, Lui GC, Wong VW. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int 2020;40:549-57. [PMID: 31845462 DOI: 10.1111/liv.14330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Peng CW, Jeng WJ. The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients. Hepatol Int 2021;15:527-8. [PMID: 33904110 DOI: 10.1007/s12072-021-10168-9] [Reference Citation Analysis]
6 Pol S. Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice. Gastroenterology 2021:S0016-5085(21)04075-0. [PMID: 34914942 DOI: 10.1053/j.gastro.2021.12.240] [Reference Citation Analysis]
7 Liaw YF, Jeng WJ. Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients. Gut 2020;69:1898-9. [PMID: 31784470 DOI: 10.1136/gutjnl-2019-320341] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Chen MB, Wang H, Zheng QH, Zheng XW, Fan JN, Ding YL, Niu JL. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis. PLoS One 2019;14:e0224773. [PMID: 31751366 DOI: 10.1371/journal.pone.0224773] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
9 Wang M, Qian M, Fu R, Zhang Y, Shen X, Yue D, Wang N, Yang L. The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Front Public Health 2021;9:709220. [PMID: 34568257 DOI: 10.3389/fpubh.2021.709220] [Reference Citation Analysis]
10 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
11 Gara N, Tana MM, Kattapuram M, Auh S, Sullivan L, Fryzek N, Walter M, Umarova R, Zhao X, Cloherty G, Doo E, Heller T, Liang TJ, Ghany MG. Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. Hepatol Commun 2021;5:1888-900. [PMID: 34558806 DOI: 10.1002/hep4.1761] [Reference Citation Analysis]
12 Wübbolding M, Lopez Alfonso JC, Lin CY, Binder S, Falk C, Debarry J, Gineste P, Kraft ARM, Chien RN, Maasoumy B, Wedemeyer H, Jeng WJ, Meyer Hermann M, Cornberg M, Höner Zu Siederdissen C. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. Hepatol Commun 2021;5:97-111. [PMID: 33437904 DOI: 10.1002/hep4.1626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Akbar SMF, Yoshida O, Hiasa Y. Immune therapies against chronic hepatitis B. J Gastroenterol 2022. [PMID: 35708793 DOI: 10.1007/s00535-022-01890-8] [Reference Citation Analysis]
14 van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
16 Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Reference Citation Analysis]
17 Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2021:gutjnl-2020-323979. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
18 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
19 Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Reference Citation Analysis]
20 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
21 Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Khan S, Penton E, Gerardo GN, Hiasa Y. The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial. Vaccines (Basel) 2021;10:45. [PMID: 35062707 DOI: 10.3390/vaccines10010045] [Reference Citation Analysis]
22 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology 2021;73:843-52. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
23 Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens 2021;10:1440. [PMID: 34832596 DOI: 10.3390/pathogens10111440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. WJGPT 2021;12:56-78. [DOI: 10.4292/wjg.v12.i4.56] [Reference Citation Analysis]
25 Kao JH, Berg T. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut 2019;68:2105-6. [PMID: 31527067 DOI: 10.1136/gutjnl-2019-319648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Xia M, Chi H, Wu Y, Hansen BE, Li Z, Liu S, Liao G, Zhang X, Zhou B, Hou J, Sun J, Janssen HLA, Peng J. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Aliment Pharmacol Ther 2021;54:709-14. [PMID: 34275138 DOI: 10.1111/apt.16538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatol Commun 2021. [PMID: 34894108 DOI: 10.1002/hep4.1875] [Reference Citation Analysis]
28 Hall SAL, Burns GS, Anagnostou D, Vogrin S, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Angus P, Sinclair M, Meredith C, Matthews G, Revill PA, Jackson K, Littlejohn M, Bowden DS, Locarnini SA, Visvanathan K, Thompson AJ. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. Aliment Pharmacol Ther 2022;56:310-20. [PMID: 35521992 DOI: 10.1111/apt.16968] [Reference Citation Analysis]
29 Fu J, Ding Z, Chen Q, Lin K, Liu H, Gao Y, Zeng Y, Li H, Shen F, Liu J. Distinct Impacts of Pre-Operative Antiviral Treatment on Post-Operative Outcomes of HBV-related Hepatocellular Carcinoma: A Landmark Analysis. J Cancer 2021;12:170-80. [PMID: 33391413 DOI: 10.7150/jca.47125] [Reference Citation Analysis]
30 Su TH, Kao JH. Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective. Clin Liver Dis (Hoboken) 2020;16:244-8. [PMID: 33489096 DOI: 10.1002/cld.950] [Reference Citation Analysis]
31 Broquetas T, Hernandez J, Garcia-retortillo M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Garrido E, Mico M, Bessa X, Carrión JA. On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2021.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Goh ZY, Ren EC, Ko HL. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. World J Gastroenterol 2021; 27(14): 1369-1391 [PMID: 33911462 DOI: 10.3748/wjg.v27.i14.1369] [Reference Citation Analysis]
33 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(4): 56-78 [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Reference Citation Analysis]
34 Liem KS, Gehring AJ, Feld JJ, Janssen HL. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 2020;158:1185-90. [DOI: 10.1053/j.gastro.2019.10.050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
35 Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clin Gastroenterol Hepatol 2020:S1542-3565(20)31662-1. [PMID: 33309804 DOI: 10.1016/j.cgh.2020.12.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
37 Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022;10:746. [DOI: 10.3390/vaccines10050746] [Reference Citation Analysis]
38 Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol 2019;13:1065-76. [PMID: 31663387 DOI: 10.1080/17474124.2019.1686975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
39 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
40 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep. 2020;2:100112. [PMID: 32462119 DOI: 10.1016/j.jhepr.2020.100112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
42 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
43 Wübbolding M, Cornberg M, Höner zu Siederdissen C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 2019;18:512-21. [DOI: 10.1007/s11901-019-00502-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Sonneveld M, Chiu S, Park J, Brakenhoff S, Kaewdech A, Seto W, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn S, Dalekos G, Erler N, Höner zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen M, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen C, Maasoumy B. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
45 Kuipery A, Mahamed D, Nkongolo S, D’angelo JA, Johnson Valiente A, Mehrotra A, Chapman WC, Horton P, Mcgilvray I, Janssen HLA, Gehring AJ. The Human Male Liver Is Predisposed to Inflammation Via Enhanced Myeloid Responses to Inflammatory Triggers. Front Immunol 2022;13:818612. [DOI: 10.3389/fimmu.2022.818612] [Reference Citation Analysis]
46 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
47 Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, Dusheiko G, Agarwal K. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology 2020;72:42-57. [PMID: 31701544 DOI: 10.1002/hep.31026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 26.5] [Reference Citation Analysis]
48 Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
49 Seto WK, Liu KS, Mak LY, Cloherty G, Wong DK, Gersch J, Lam YF, Cheung KS, Chow N, Ko KL, To WP, Fung J, Yuen MF. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut 2021;70:775-83. [PMID: 32759300 DOI: 10.1136/gutjnl-2020-321116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
50 Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14:657. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Choi HSJ, Sonneveld MJ, Farag MS, Brouwer WP, Brakenhoff SM, Hirode G, Gehring AJ, de Man RA, Hansen BE, Janssen HLA. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. J Viral Hepat 2021;28:1729-37. [PMID: 34514678 DOI: 10.1111/jvh.13613] [Reference Citation Analysis]
52 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
53 Akbar SMF, Al Mahtab M, Begum F, Hossain SAS, Sarker S, Shrestha A, Khan MSI, Yoshida O, Hiasa Y. Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia. Vaccines (Basel) 2021;9:374. [PMID: 33921259 DOI: 10.3390/vaccines9040374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]